{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Osteoporosis: A Review of Novel Agents

Activity Steps


This article has been approved by the Orthopaedic Nurses Certification Board for Category A credit toward recertification as an ONC.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify recommendations for the prevention of osteoporosis.
  2. Explain issues related to screening for osteoporosis.
  3. Outline the education of a patient who will be taking romosozumab.
  4. Explain safety issues related to abaloparatide.

Learning Outcomes

Seventy-five percent of participants will demonstrate competency in clinical reasoning regarding the screening for and prevention and treatment of osteoporosis by achieving a minimum score of 70% on the outcomes-based posttest.
Price: $20.00


  • ANCC 2.0 CH
  • DC - BON 2.0 CH
  • FL - BON 2.0 CH
  • GA - BON 2.0 CH
  • NM - BON 2.0 CH
  • SC - BON 2.0 CH
  • WV - BOERN 2.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.

Test Code: ON1122C
Published: Nov/Dec 2022
Expires: 9/5/2025
Required Passing Score: 8/10 (80%)
Authors: Khyati Patel, PharmD, BCACP; Shereen Salama, PharmD; Jessica Cottreau, PharmD, BCPS, BCIDP